Preferred Label : Mirzotamab Clezutoclax;
NCIt synonyms : ADC ABBV-155; Antibody-drug Conjugate ABBV-155;
NCIt definition : An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the immunoregulatory
protein B7-homologue 3 (B7-H3, CD276) conjugated, via a solubilizing linker, to a
B-cell lymphoma extra long (Bcl-XL) inhibitor, with potential antineoplastic activity.
Upon administration of mirzotamab clezutoclax, the anti-B7-H3 monoclonal antibody
moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization
and linker cleavage, the Bcl-XL inhibitor targets, binds to and inhibits the activity
of the pro-survival protein Bcl-XL. This restores apoptotic processes and inhibits
the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein
and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain
tumor cell types and on various immune cells. It plays a key role in tumor growth
and immune responses.;
UNII : TY49T0B03B;
CAS number : 2229859-12-3;
Molecule name : ABBV 155; ABBV-155;
NCI Metathesaurus CUI : CL937020;
Origin ID : C157279;
UMLS CUI : C5418263;
Currated CISMeF NLP mapping
- Semantic type(s)
- concept_is_in_subset
- has_target
